Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal


Klassificering: A

Preparat: Benepali, Enbrel®, Erelzi

ATC kod: L04AB01

Substanser: etanercept


Evidensen för etanercept-specifika kön- och genusskillnader är bristfällig. Studier på TNF-hämmare vid flera indikationer har visat sämre behandlingssvar och större benägenhet att avbryta behandlingen hos kvinnor. Orsakerna till detta är oklara. Incidensen av hudbiverkningar vid TNF-hämmarbehandling är högre för kvinnor än för män. Registerstudier har visat att kvinnor med reumatoid artrit initieras på TNF-hämmarbehandling vid en högre nivå av självupplevd sjukdomsaktivitet men på samma nivå av läkarrapporterad sjukdomsaktivitet.

Additional information

The prevalence of rheumatoid arthritis in the adult Swedish population is 0.7% and it is two-to-three times more common in women than in men [1]. The prevalence of ankylosing spondylitis in the Swedish adult population is 0.2%, with more men than women affected (0.23% vs. 0.14%) [2]. The overall prevalence of psoriasis in the adult Swedish population is 1.2%, psoriatic arthritis affects about 20% of these patients. In both psoriasis and psoriatic arthritis men and women are affected equally [3].

Pharmacokinetics and dosing

Pharmacokinetic parameters were examined in a study that combined samples from patients with rheumatoid arthritis in an open-label pharmacokinetic study (10 men, 15 women), with patients from a randomized clinical trial (11 men, 66 women). There was no difference between men and women in the clearance or half-life of etanercept, although given the low number of men included, small differences could not be ruled out [4]. In a larger pharmacokinetics study, data from three randomized controlled trials on etanercept in psoriasis were pooled together (718 men, 359 women). Clearance was 12% higher in women than in men but given the large overall variability in clearance the authors did not consider this to be of any clinical significance [5]. The prescribing information states that in clinical studies pharmacokinetic parameters were not different between men and women and did not vary with age in adult patients [6].


Rheumatoid arthritisSeveral studies have shown that men have a greater chance to achieve remission in rheumatoid arthritis (RA). A large observational study involving RA patients (165 men, 840 women) found a relative risk of 1.51 for remission in men within the first 14.5 months of therapy with standard doses of TNF-inhibitors (infliximab, etanercept or adalimumab) [7]. A register-based study (3 465 men, 10 971 women) with RA patients treated with TNF inhibitors (33% etanercept) examined factors predictive of sustained remission. Female sex was associated with a lower chance of achieving sustained remission (Odds ratio (OR) 0.59) and sustained low disease activity (OR 0.65,) [8]. Similar results were reported in a meta-analysis which found an OR of 0.53  for women to achieve sustained remission with TNF inhibitor therapy in RA (3729 patients, 77% women) [9]. In a smaller observational study of patients with established RA (353 men, 1212 women) patient’s sex did not predict the response to TNF inhibitors (infliximab, etanercept or adalimumab) [10].

Axial spondyloarthritis and psoriatic arthritisA register-based study on spondyloarthritis patients (1601 men, 919 women) initiating TNF inhibitor therapy (etanercept n=745) examined factors that influenced drug discontinuation. Risk of drug discontinuation was lower in men than in women (hazard ratio (HR) 0.66) [11].  An observational study on patients with axial spondyloarthritis (236 men, 104 women) assessed the influence of patient’s sex on response to TNF inhibitor treatment (etanercept n=96) and disease remission. The probability of achieving partial remission was two to three times higher in men than in women [12].Predictors of response to TNF inhibitors in patients with ankylosing spondylitis and psoriatic arthritis were analyzed in a systematic review and meta-analysis that included 56 observational studies and randomized trials. In ankylosing spondylitis, male sex was associated with an OR of 1.57 for achieving clinical response as measured by the Bath Ankylosing Spondylitis Disease Activity Index 50 (BASDAI50). In psoriatic arthritis, men showed better response than women in five out of eight studies that included data on demographics but was not identified as a predictor of response [13]. A later observational study included patients (35 men, 40 women) initiated on TNF inhibitor treatment (etanercept, golimumab and adalimumab) and were followed prospectively. After twelve months, minimal disease activity was achieved in 61% of the patients. Male sex was associated with two to three times higher odds of achieving response, no difference was seen between the different TNF inhibitors [14].A systematic literature review found eight studies that examined differences between men and women in treatment discontinuation of TNF inhibitors in psoriatic arthritis. A higher risk of treatment discontinuation for women was reported in the majority of the included studies (n=3950 patients, about 45% women) [15].

PsoriasisAn observational study on patients with psoriasis that initiated biologic treatment (etanercept, adalimumab or ustekinumab) examined factors associated with response. The study included 3079 patients with data on baseline and six-month disease activity, 713 of these patients were started on etanercept (430 men, 283 women). Among all patients, female sex was associated with reduced odds of achieving ≥ 90% improvement in Psoriasis Area and Severity Index (PASI 90) (OR 0.78,). Chance of achieving PASI90 was lower for etanercept-treated compared to adalimumab-treated (OR 0.25). However, there was some evidence of a comparatively better response to etanercept for women, than men [16].

Adverse effects

The risk of cutaneous adverse events was examined in an observational study that included 5 437 arthritis patients treated with TNF inhibitors (644 men, 961 women with etanercept). Female sex was associated with a higher risk of cutaneous adverse events (incidence rate ratio 1.49) among all TNF inhibitor treated patients [17]. A similar observational study examined the incidence of cutaneous adverse events among TNF inhibitor-treated patients with chronic inflammatory arthritis (92 men, 165 women). After five years of follow-up, 71 (27.6%) patients experienced some type of adverse event involving the skin. Female sex was strongly linked to risk of cutaneous adverse events (OR 2.84) [18]. Another observational study examined drug discontinuation in biologics-treated psoriasis (etanercept, adalimumab or ustekinumab). The study included 226 men and 145 women and found that female sex predicted drug discontinuation due to adverse events in etanercept (HR 2.33), as well as in adalimumab and ustekinumab [19].


Reproductive health issues

Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).

Other information

A register-based study (2204 men, 7098 women) examined differences in disease characteristics at initiation of TNF inhibitors (etanercept, adalimumab and infliximab) between men and women. In women with rheumatoid arthritis, TNF inhibitor therapy was initiated at a higher level of patient reported disease activity than men. Except for slightly higher levels of c-reactive protein among men, physician-reported disease activity did not differ between the sexes [20]. A subsequent study (402 men, 1510 women) confirmed these results, however some of the patients were included in both studies [21].

Several studies have shown that the delay to initiation of therapy for patients with RA is similar for men and women and that no differences in the proportion of men and women receiving biologic agents have been found [22, 23].

Adherence to TNF inhibitors (etanercept, infliximab, adalimumab) in RA and Crohn’s disease was examined in a systematic review. Although there were some important differences, adherence was consistently lower in women [24].

Patients with rheumatic disease treated with etanercept (n=24) did not develop anti-drug antibodies in a clinical study. However, female sex was associated with development of anti-drug antibodies against adalimumab and infliximab [25].

Försäljning på recept

Fler kvinnor än män hämtade ut läkemedel innehållande etanercept (ATC-kod L04AB01) på recept i Sverige år 2021, totalt 8 451 kvinnor och 5 136 män. Det motsvarar 1,6 respektive 1,0 personer per tusen invånare. Andelen som hämtat ut läkemedel var högst i åldersgruppen 65-69 år hos båda könen. I genomsnitt var läkemedel innehållande etanercept 1,8 gånger vanligare hos kvinnor [26].

Uppdaterat: 2022-11-08

Litteratursökningsdatum: 2022-10-07


  1. Englund M, Jöud A, Geborek P, Felson DT, Jacobsson LT, Petersson IF. Prevalence and incidence of rheumatoid arthritis in southern Sweden 2008 and their relation to prescribed biologics. Rheumatology (Oxford). 2010;49(8):1563-9. PubMed
  2. Exarchou S, Lindström U, Askling J, Eriksson JK, Forsblad-d'Elia H, Neovius M et al. The prevalence of clinically diagnosed ankylosing spondylitis and its clinical manifestations: a nationwide register study. Arthritis Res Ther. 2015;17(1):118. PubMed
  3. Löfvendahl S, Theander E, Svensson Å, Carlsson KS, Englund M, Petersson IF. Validity of diagnostic codes and prevalence of physician-diagnosed psoriasis and psoriatic arthritis in southern Sweden--a population-based register study. PLoS One. 2014;9(5):e98024. PubMed
  4. Lee H, Kimko HC, Rogge M, Wang D, Nestorov I, Peck CC. Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. Clin Pharmacol Ther. 2003;73(4):348-65. PubMed
  5. Nestorov I, Zitnik R, Ludden T. Population pharmacokinetic modeling of subcutaneously administered etanercept in patients with psoriasis. J Pharmacokinet Pharmacodyn. 2004;31(6):463-90. PubMed
  6. Food and Drug Administration (FDA). Prescribing information - Enbrel (etanercept). Drugs@FDA [www]. [updated 2012-12-01, cited 2022-10-02]. länk
  7. Atzeni F, Antivalle M, Pallavicini FB, Caporali R, Bazzani C, Gorla R et al. Predicting response to anti-TNF treatment in rheumatoid arthritis patients. Autoimmun Rev. 2009;8:431-7. PubMed
  8. Hamann PDH, Pauling JD, McHugh N, Shaddick G, Hyrich K, BSRBR-RA Contributors Group. Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factor-treated rheumatoid arthritis patients. Rheumatology (Oxford). 2019;58(12):2162-2169. PubMed
  9. Hamann P, Holland R, Hyrich K, Pauling JD, Shaddick G, Nightingale A et al. Factors Associated With Sustained Remission in Rheumatoid Arthritis in Patients Treated With Anti-Tumor Necrosis Factor. Arthritis Care Res (Hoboken). 2017;69(6):783-793. PubMed
  10. Kristensen LE, Kapetanovic MC, Gülfe A, Söderlin M, Saxne T, Geborek P. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford). 2008;47:495-9. PubMed
  11. Lie E, Kristensen LE, Forsblad-d'Elia H, Zverkova-Sandström T, Askling J, Jacobsson LT et al. The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study. Ann Rheum Dis. 2015;74(6):970-8. PubMed
  12. Lubrano E, Perrotta FM, Manara M, D'Angelo S, Addimanda O, Ramonda R et al. The Sex Influence on Response to Tumor Necrosis Factor-α Inhibitors and Remission in Axial Spondyloarthritis. J Rheumatol. 2018;45(2):195-201. PubMed
  13. Maneiro JR, Souto A, Salgado E, Mera A, Gomez-Reino JJ. Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis. RMD Open. 2015;1(1):e000017. PubMed
  14. Perrotta FM, Marchesoni A, Lubrano E. Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs. J Rheumatol. 2016;43(2):350-5. PubMed
  15. Generali E, Sciré CA, Cantarini L, Selmi C. Sex Differences in the Treatment of Psoriatic Arthritis: A Systematic Literature Review. Isr Med Assoc J. 2016;18:203-8. PubMed
  16. Warren RB, Marsden A, Tomenson B, Mason KJ, Soliman MM, Burden AD et al. Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. Br J Dermatol. 2019;180(5):1069-1076. PubMed
  17. Hernández MV, Sanmartí R, Cañete JD, Descalzo MA, Alsina M, Carmona L et al. Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases. Arthritis Care Res (Hoboken). 2013;65:2024-31. PubMed
  18. Machado NP, Reis Neto ET, Soares MR, Freitas DS, Porro A, Ciconelli RM et al. The skin tissue is adversely affected by TNF-alpha blockers in patients with chronic inflammatory arthritis: a 5-year prospective analysis. Clinics (Sao Paulo). 2013;68:1189-96. PubMed
  19. Zweegers J, van den Reek JM, van de Kerkhof PC, Otero ME, Kuijpers AL, Koetsier MI et al. Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry. Br J Dermatol. 2016;175(2):340-7. PubMed
  20. Arkema EV, Neovius M, Joelsson JK, Simard JF, van Vollenhoven RF. Is there a sex bias in prescribing anti-tumour necrosis factor medications to patients with rheumatoid arthritis? A nation-wide cross-sectional study. Ann Rheum Dis. 2012;71:1203-6. PubMed
  21. Lesuis N, Befrits R, Nyberg F, van Vollenhoven RF. Gender and the treatment of immune-mediated chronic inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and psoriasis: an observational study. BMC Med. 2012;10:82. PubMed
  22. Sokka T, Toloza S, Cutolo M, Kautiainen H, Makinen H, Gogus F et al. Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study. Arthritis Res Ther. 2009;11:R7. PubMed
  23. DeWitt EM, Lin L, Glick HA, Anstrom KJ, Schulman KA, Reed SD. Pattern and predictors of the initiation of biologic agents for the treatment of rheumatoid arthritis in the United States: an analysis using a large observational data bank. Clin Ther. 2009;31:1871-80; discussion 1858. PubMed
  24. Fidder HH, Singendonk MM, van der Have M, Oldenburg B, van Oijen MG. Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn's disease and rheumatoid arthritis: results of a systematic review. World J Gastroenterol. 2013;19:4344-50. PubMed
  25. Mok CC, van der Kleij D, Wolbink GJ. Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases. Clin Rheumatol. 2013;32:1429-35. PubMed
  26. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2021 [cited 2022-03-15.] länk

Författare: Hjalmar Wadström

Faktagranskat av: Diana Rydberg, Carl-Olav Stiller

Godkänt av: Karin Schenck-Gustafsson